胶质母细胞瘤（GB）仍然是一个艰巨的挑战，需要新的治疗策略。泛素蛋白酶体系统（UPS）是细胞调节中的重要组成部分，鉴于其肿瘤基因的失调，使其成为 GB 治疗的潜在关键靶点。 UPS 系统中的泛素特异性蛋白酶 (USP) 被认为是由于在与癌基因相关的细胞过程中的花园作用及其在细胞凋亡过程、细胞周期调节和自噬中的重要功能。本文全面总结了将 USP 作为肿瘤治疗潜在因素的证据基础。该综述考虑了 UPS 系统在开发中的参与，从而得出 p53、Rb 和 NF-κB 的重要性，并评估了使用午夜蛋白酶体抑制剂以及 E1 和 E2 酶的小分子拮抗剂进行治疗的具体目标。尽管药物创造速度放缓，但基于 USP 系统动力学的最新治疗发现为专门治疗带来了希望。该综述最后分析了未来的流浪者以及针对个性化 GB 治疗的 USP 的可行效果，这可以在当前缺乏吸引力的治疗环境中改善患者的水合作用。该手稿强调了 USP 癌基因疗法作为 GB 的一种有前途的替代治疗线的可能性。它强调直接开展对该方法的医疗效果的研究。版权所有 © 2024 Elsevier GmbH。版权所有。

Glioblastoma (GB) remains a formidable challenge and requires new treatment strategies. The vital part of the Ubiquitin-proteasome system (UPS) in cellular regulation has positioned it as a potentially crucial target in GB treatment, given its dysregulation oncolines. The Ubiquitin-specific proteases (USPs) in the UPS system were considered due to the garden role in the cellular processes associated with oncolines and their vital function in the apoptotic process, cell cycle regulation, and autophagy. The article provides a comprehensive summary of the evidence base for targeting USPs as potential factors for neoplasm treatment. The review considers the participation of the UPS system in the development, resulting in the importance of p53, Rb, and NF-κB, and evaluates specific goals for therapeutic administration using midnight proteasomal inhibitors and small molecule antagonists of E1 and E2 enzymes. Despite the slowed rate of drug creation, recent therapeutic discoveries based on USP system dynamics hold promise for specialized therapies. The review concludes with an analysis of future wanderers and the feasible effects of targeting USPs on personalized GB therapies, which can improve patient hydration in this current and unattractive therapeutic landscape. The manuscript emphasizes the possibility of USP oncogene therapy as a promising alternative treatment line for GB. It stresses the direct creation of research on the medical effectiveness of the approach.Copyright © 2024 Elsevier GmbH. All rights reserved.